Brokerages Set Silence Therapeutics plc (NASDAQ:SLN) PT at $45.00

Shares of Silence Therapeutics plc (NASDAQ:SLN) have been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $45.00.

Several equities analysts have recently issued reports on SLN shares. Chardan Capital reiterated a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a research note on Tuesday, December 10th. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, January 29th. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Finally, The Goldman Sachs Group started coverage on Silence Therapeutics in a report on Tuesday, February 11th. They issued a “sell” rating and a $6.00 target price for the company.

Silence Therapeutics Stock Performance

Shares of SLN opened at $4.50 on Thursday. Silence Therapeutics has a 52-week low of $4.06 and a 52-week high of $27.72. The business’s fifty day moving average is $5.63 and its 200-day moving average is $11.77. The firm has a market cap of $134.69 million, a price-to-earnings ratio of -2.87 and a beta of 1.05.

Hedge Funds Weigh In On Silence Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Eventide Asset Management LLC acquired a new stake in shares of Silence Therapeutics in the third quarter valued at about $11,635,000. Parkman Healthcare Partners LLC increased its stake in shares of Silence Therapeutics by 71.8% in the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after buying an additional 208,029 shares during the period. Point72 Asset Management L.P. increased its stake in shares of Silence Therapeutics by 219.3% in the third quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock valued at $8,505,000 after buying an additional 321,300 shares during the period. Janus Henderson Group PLC increased its stake in shares of Silence Therapeutics by 32.8% in the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock valued at $19,798,000 after buying an additional 268,250 shares during the period. Finally, Verition Fund Management LLC acquired a new stake in shares of Silence Therapeutics in the third quarter valued at about $207,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.